Chimagen Biosciences
Tracked across 1 events · 8 articles · First seen Sep 15, 2026 · Last active Sep 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement…
Impact: Chimagen Biosciences is the privately held seller of the trispecific TCE, receiving an upfront payment plus up to $750 million in milestone payments and gaining GSK's global development and commercial capabilities for its programme. The agreement also deepens its existing relationship with GSK following the earlier CMG1A46 deal.
Sep 15, 2026 · 8 articles
95
GSK plc acquired global rights Chimagen BiosciencesGSK Acquires Chimagen...
40
GSK plc agreed to acquire Chimagen BiosciencesGSK Acquires Chimagen...
ERGEN INTELLIGENCE
Track Chimagen Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard